Marc P. Schneider
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Marc P. Schneider has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Thomas Matthias Kessler
Department of Neuro-Urology, Balgrist University Hospital, University of Zürich, Zürich, Switzerland
9 shared publications Jure Tornic
Department of Neuro-Urology, Balgrist University Hospital, University of Zürich, Zürich, Switzerland
4 shared publications- Lorenz Leitner
Department of Neuro-Urology, Balgrist University Hospital, University of Zürich, Zürich, Switzerland
4 shared publications - Matthias Walter
University of Twente Enschede The Netherlands
4 shared publications - Ulrich Mehnert
Department of Neuro-Urology, Balgrist University Hospital, University of Zürich, Zürich, Switzerland
4 shared publications Emmanuel Chartier‐Kastler
Department of Urology, Pitié-Salpêtrière Academic Hospital, School of Medicine, Sorbonne University, Paris, France
3 shared publications
Latest Publications
- Open Access
- 1 May 2020
- Published by Elsevier in Urology Case Reports
- Vol. 30, 101070
Duplicated collecting system with ectopic prostatic implantation: Therapeutic conservative robot assisted approach, about a case report
- 1 May 2020
- Published by Elsevier in Urology Case Reports
- Vol. 30, 101070
Open AccessDuplicated collecting system with ectopic prostatic implantation: Therapeutic conservative robot assisted approach, about a case report
- 16 May 2019
- Published by Wiley in Neurourology and Urodynamics
- Vol. 38 (6) , 1482-1491
Alpha‐blockers for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: A systematic review and meta‐analysis. A report from the Neuro‐Urology Promotion Committee of the International Continence Society (ICS)
Aim: We aimed to systematically assess the evidence on the efficacy and safety of alpha‐blockers in patients with multiple sclerosis (MS) suffering from neurogenic lower urinary tract dysfunction (NLUTD).Methods: The Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement was used to perform this systematic review. An electronic search of Cochrane register, Embase, Medline, Scopus (last search 3 March 2018) and screening of reference lists as well as reviews were used to identify the studies. Articles were included if they reported on efficacy/safety of alpha‐blockers for the treatment of NLUTD in patients with MS.Results: After screening of 7′015 abstracts, three studies enrolling a total of 50 patients were included: one randomized, placebo‐controlled, single‐blind trial and two prospective cohort studies. Alpha‐blocker treatment was successful in 50% to 96% of the patients. Pooling data from the three included studies, the relative risk for successful alpha‐blocker treatment was 3.89 (95% confidence interval 2.7‐7.0). The general safety profile of alpha‐blockers was favorable with 8% of the patients reporting adverse events.Conclusions: Alpha‐blockers may be effective and safe for treating NLUTD in female and male patients with MS but the studies were small and the overall quality of evidence was low. To make definitive conclusions, well designed randomized controlled trials are highly warranted.
- 16 May 2019
- Published by Wiley in Neurourology and Urodynamics
- Vol. 38 (6) , 1482-1491
Alpha‐blockers for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: A systematic review and meta‐analysis. A report from the Neuro‐Urology Promotion Committee of the International Continence Society (ICS)
Aim: We aimed to systematically assess the evidence on the efficacy and safety of alpha‐blockers in patients with multiple sclerosis (MS) suffering from neurogenic lower urinary tract dysfunction (NLUTD).Methods: The Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement was used to perform this systematic review. An electronic search of Cochrane register, Embase, Medline, Scopus (last search 3 March 2018) and screening of reference lists as well as reviews were used to identify the studies. Articles were included if they reported on efficacy/safety of alpha‐blockers for the treatment of NLUTD in patients with MS.Results: After screening of 7′015 abstracts, three studies enrolling a total of 50 patients were included: one randomized, placebo‐controlled, single‐blind trial and two prospective cohort studies. Alpha‐blocker treatment was successful in 50% to 96% of the patients. Pooling data from the three included studies, the relative risk for successful alpha‐blocker treatment was 3.89 (95% confidence interval 2.7‐7.0). The general safety profile of alpha‐blockers was favorable with 8% of the patients reporting adverse events.Conclusions: Alpha‐blockers may be effective and safe for treating NLUTD in female and male patients with MS but the studies were small and the overall quality of evidence was low. To make definitive conclusions, well designed randomized controlled trials are highly warranted.
- Open Access
- 15 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e2119
Benefits and harms of electrical neuromodulation for chronic pelvic pain: A systematic review
- 15 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e2119
Open AccessBenefits and harms of electrical neuromodulation for chronic pelvic pain: A systematic review
- 15 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e2
Anti-Nogo-A antibodies: Promising treatment for neurogenic lower urinary tract dysfunction after spinal cord injury
- 15 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e2
Anti-Nogo-A antibodies: Promising treatment for neurogenic lower urinary tract dysfunction after spinal cord injury
- 17 January 2019
- Published by Wiley in Neurourology and Urodynamics
- Vol. 38 (2) , 563-571
Desmopressin for treating nocturia in patients with multiple sclerosis: A systematic review: A report from the Neuro‐Urology Promotion Committee of the International Continence Society (ICS)
Aims To systematically assess all available evidence on efficacy and safety of desmopressin for treating nocturia in patients with multiple sclerosis (MS). Methods This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement. Studies were identified by electronic search of Cochrane register, Embase, Medline, Scopus (last search March 3, 2018) and by screening of reference lists and reviews. Results After screening of 7015 abstracts, 8 prospective, and 1 retrospective studies were included enrolling a total of 178 patients. The mean patient age ranged between 43 and 51 years. A significant decrease in the number of micturitions per night was reported in 5 studies. An increase in the maximum hours of uninterrupted sleep was only found in two studies. A significant reduction of the volume of nocturnal incontinence was described in one study. The patient satisfaction rates ranged from 56% to 82%. The rate of adverse events was between 0% and 57.9%. The rate of hyponatremia ranged from 0% to 23.5% and other commonly reported adverse events were headache, nausea, fluid retention, rhinitis/epistaxis, malaise, and swollen ankles. Risk of bias and confounding was relevant in all studies. Conclusions Preliminary data suggest that desmopressin might be effective for treating nocturia in patients with MS. However, adverse events are relatively common, the overall quality of evidence is low and the number of studied patients is very limited. Further studies with newer formulations of desmopressin are highly warranted.
- 17 January 2019
- Published by Wiley in Neurourology and Urodynamics
- Vol. 38 (2) , 563-571
Desmopressin for treating nocturia in patients with multiple sclerosis: A systematic review: A report from the Neuro‐Urology Promotion Committee of the International Continence Society (ICS)
Aims To systematically assess all available evidence on efficacy and safety of desmopressin for treating nocturia in patients with multiple sclerosis (MS). Methods This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement. Studies were identified by electronic search of Cochrane register, Embase, Medline, Scopus (last search March 3, 2018) and by screening of reference lists and reviews. Results After screening of 7015 abstracts, 8 prospective, and 1 retrospective studies were included enrolling a total of 178 patients. The mean patient age ranged between 43 and 51 years. A significant decrease in the number of micturitions per night was reported in 5 studies. An increase in the maximum hours of uninterrupted sleep was only found in two studies. A significant reduction of the volume of nocturnal incontinence was described in one study. The patient satisfaction rates ranged from 56% to 82%. The rate of adverse events was between 0% and 57.9%. The rate of hyponatremia ranged from 0% to 23.5% and other commonly reported adverse events were headache, nausea, fluid retention, rhinitis/epistaxis, malaise, and swollen ankles. Risk of bias and confounding was relevant in all studies. Conclusions Preliminary data suggest that desmopressin might be effective for treating nocturia in patients with MS. However, adverse events are relatively common, the overall quality of evidence is low and the number of studied patients is very limited. Further studies with newer formulations of desmopressin are highly warranted.
- 19 June 2018
- Published by Wiley in Neurourology and Urodynamics
- Vol. 37 (8) , 2315-2322
Catheterization for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: A systematic review. A report from the Neuro‐Urology Promotion Committee of the International Continence Society (ICS)
Aim: To systematically assess all available evidence on efficacy and safety of catheterization for treating neurogenic lower urinary tract dysfunction (NLUTD) in patients with multiple sclerosis (MS).Methods: This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement. Studies were identified by electronic search of Embase, Medline, Scopus, Cochrane register (last search March 3, 2018) and by screening of reference lists and reviews.Results: After screening 7′015 articles, we included four studies (one prospective and two retrospective cohort studies, one retrospective cross‐sectional study), in which a total of 445 patients were enrolled. No randomized controlled trial was available. Catheterization substantially increased quality of life, post void residual, and incontinence episodes in all included studies. Pooling of data for meta‐analysis was not possible due to the heterogeneity of reported outcomes. Adverse events were reported in two studies only. Risk of bias and confounding was intermediate.Conclusions: Preliminary data suggests beneficial effects of catheterization on the urological outcome in patients with MS. However, although intermittent and indwelling catheterization is used frequently in daily clinical practice in the MS population, the evidence base is very limited and well‐designed, properly sampled, and powered studies are urgently needed.
- 19 June 2018
- Published by Wiley in Neurourology and Urodynamics
- Vol. 37 (8) , 2315-2322
Catheterization for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: A systematic review. A report from the Neuro‐Urology Promotion Committee of the International Continence Society (ICS)
Aim: To systematically assess all available evidence on efficacy and safety of catheterization for treating neurogenic lower urinary tract dysfunction (NLUTD) in patients with multiple sclerosis (MS).Methods: This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement. Studies were identified by electronic search of Embase, Medline, Scopus, Cochrane register (last search March 3, 2018) and by screening of reference lists and reviews.Results: After screening 7′015 articles, we included four studies (one prospective and two retrospective cohort studies, one retrospective cross‐sectional study), in which a total of 445 patients were enrolled. No randomized controlled trial was available. Catheterization substantially increased quality of life, post void residual, and incontinence episodes in all included studies. Pooling of data for meta‐analysis was not possible due to the heterogeneity of reported outcomes. Adverse events were reported in two studies only. Risk of bias and confounding was intermediate.Conclusions: Preliminary data suggests beneficial effects of catheterization on the urological outcome in patients with MS. However, although intermittent and indwelling catheterization is used frequently in daily clinical practice in the MS population, the evidence base is very limited and well‐designed, properly sampled, and powered studies are urgently needed.
- Open Access
- 1 April 2018
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 199 (4S)
PD36-07 PREDICTION OF AUTONOMIC DYSREFLEXIA DURING URODYNAMICS
- 1 April 2018
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 199 (4S)
Open AccessPD36-07 PREDICTION OF AUTONOMIC DYSREFLEXIA DURING URODYNAMICS
- 2 February 2018
- Published by Wiley in Neurourology and Urodynamics
- Vol. 37 (5) , 1522-1540
Value of urodynamic findings in predicting upper urinary tract damage in neuro‐urological patients: A systematic review
Aim: The main goals of neurogenic lower urinary tract dysfunction (NLUTD) management are preventing upper urinary tract damage (UUTD), improving continence, and quality of life. Here, we aimed to systematically assess all available evidence on urodynamics predicting UUTD in patients with NLUTD.Methods: A systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) Statement was performed in March 2017. Only neuro‐urological patients assessed by urodynamics were included. Any outcome of upper urinary tract function were evaluated.Results: Forty‐nine studies (1 randomized controlled trial, 9 prospective, and 39 retrospective case series) reported urodynamic data on 4930 neuro‐urological patients. Of those, 2828 (98%) were spina bifida (SB) children. The total number of adults was 2044, mainly having spinal cord injury (SCI) (60%). A low bladder compliance was found in 568 (46.3%) and 341 (29.3%) of the paediatric and adult population, respectively. Hydronephrosis (HDN) was detected in 557 children (27.8%) in 19/28 studies and 178 adults (14.6%), mainly SCI, in 14/21 studies. Nine out of 30 multiple sclerosis (MS) patients affected by HDN (16.8%) showed low compliance in 4/14 studies.Conclusions: Patients with SB and SCI have a higher risk of developing UUTD (mainly reported as HDN) compared to those with MS. Reduced compliance and high DLPP were major risk factors for UUTD. Although our findings clarify the mandatory role of urodynamics in the management of NLUTD, standardization and better implementation of assessments in daily practice may further improve outcomes of neuro‐urological patients based on objective measurements, that is, urodynamics.
- 2 February 2018
- Published by Wiley in Neurourology and Urodynamics
- Vol. 37 (5) , 1522-1540
Value of urodynamic findings in predicting upper urinary tract damage in neuro‐urological patients: A systematic review
Aim: The main goals of neurogenic lower urinary tract dysfunction (NLUTD) management are preventing upper urinary tract damage (UUTD), improving continence, and quality of life. Here, we aimed to systematically assess all available evidence on urodynamics predicting UUTD in patients with NLUTD.Methods: A systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) Statement was performed in March 2017. Only neuro‐urological patients assessed by urodynamics were included. Any outcome of upper urinary tract function were evaluated.Results: Forty‐nine studies (1 randomized controlled trial, 9 prospective, and 39 retrospective case series) reported urodynamic data on 4930 neuro‐urological patients. Of those, 2828 (98%) were spina bifida (SB) children. The total number of adults was 2044, mainly having spinal cord injury (SCI) (60%). A low bladder compliance was found in 568 (46.3%) and 341 (29.3%) of the paediatric and adult population, respectively. Hydronephrosis (HDN) was detected in 557 children (27.8%) in 19/28 studies and 178 adults (14.6%), mainly SCI, in 14/21 studies. Nine out of 30 multiple sclerosis (MS) patients affected by HDN (16.8%) showed low compliance in 4/14 studies.Conclusions: Patients with SB and SCI have a higher risk of developing UUTD (mainly reported as HDN) compared to those with MS. Reduced compliance and high DLPP were major risk factors for UUTD. Although our findings clarify the mandatory role of urodynamics in the management of NLUTD, standardization and better implementation of assessments in daily practice may further improve outcomes of neuro‐urological patients based on objective measurements, that is, urodynamics.
- 15 November 2017
- Published by Wiley in Neurourology and Urodynamics
- Vol. 37 (4) , 1266-1271
Urodynamic measurements reflect physiological bladder function in rats
Aims: Our objective was to investigate and compare bladder function in rats assessed by metabolic cage and by urodynamic measurements in fully awake animals.Methods: Bladder function of female Lewis rats was investigated in naïve animals by metabolic cage at baseline, 14‐16 days after bladder catheter and external urethral sphincter electromyography electrode implantation in fully awake animals by urodynamics, and again by metabolic cage.Results: Investigating the same animals (n = 8), voided volume, average flow, and duration of voiding were similar (P > 0.05) in naïve animals measured by metabolic cage and after catheter implantation by urodynamic measurements and by metabolic cage. In naïve animals measured by metabolic cage, voided volumes were significantly different in the light (resting phase) versus the dark (active phase) part of the 24 h cycle (mean difference 0.14 mL, 21%, P = 0.004, n = 27).Conclusions: Lower urinary tract function assessed by metabolic cage or by urodynamic meaurements in fully awake rats was indistinguishable. Thus, catheter implantation did not significantly change physiological bladder function. This shows that urodynamic measurements in awake animals are an appropriate approach to study lower urinary tract function in health and disease in animal models, directly paralleling the human diagnostic procedures.
- 15 November 2017
- Published by Wiley in Neurourology and Urodynamics
- Vol. 37 (4) , 1266-1271
Urodynamic measurements reflect physiological bladder function in rats
Aims: Our objective was to investigate and compare bladder function in rats assessed by metabolic cage and by urodynamic measurements in fully awake animals.Methods: Bladder function of female Lewis rats was investigated in naïve animals by metabolic cage at baseline, 14‐16 days after bladder catheter and external urethral sphincter electromyography electrode implantation in fully awake animals by urodynamics, and again by metabolic cage.Results: Investigating the same animals (n = 8), voided volume, average flow, and duration of voiding were similar (P > 0.05) in naïve animals measured by metabolic cage and after catheter implantation by urodynamic measurements and by metabolic cage. In naïve animals measured by metabolic cage, voided volumes were significantly different in the light (resting phase) versus the dark (active phase) part of the 24 h cycle (mean difference 0.14 mL, 21%, P = 0.004, n = 27).Conclusions: Lower urinary tract function assessed by metabolic cage or by urodynamic meaurements in fully awake rats was indistinguishable. Thus, catheter implantation did not significantly change physiological bladder function. This shows that urodynamic measurements in awake animals are an appropriate approach to study lower urinary tract function in health and disease in animal models, directly paralleling the human diagnostic procedures.